Marker Therapeutics Inc (MRKR)

[GS1]

The first thing you need to look at company fundamentals. It starts with patents. The Folate Receptor Alpha patents are very new and could have patent life for another 15-20 years. Given another 5 years will take for development it would still have 10-15 years to market. This is really attractive for big pharma if they decide to make deal.

FRA has multiple indications and it works in both Ovarian and Breast cancer. It will work in 80% of NSCLC and Colorectal cancer. The market size for these indications is huge easily 4-5 billion dollars. Do you think vaccine won't work in these indications, there is no reason to believe it wouldn't because targets are same... Hang tight..it is no brainer.

That said company still has some work to do with respect HER2neu and TAP patents. If these patents granted the valuation goes further up.